Text Size
105 studies found for:    Open Studies | "Hypercholesterolemia"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Not yet recruiting Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Interventions: Drug: Rosuvastatin + Ezetimibe;   Drug: Simvastatin + Ezetimibe
2 Recruiting Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: CER-001
3 Unknown † Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia
Condition: Primary Hypercholesterolemia
Interventions: Drug: P-OM3;   Drug: Placebo
4 Unknown † Flaxseed Compared With Placebo in Patients With Hypercholesterolemia
Condition: Familial or Severe Hypercholesterolemia
Interventions: Dietary Supplement: flaxseed;   Dietary Supplement: whole wheat flour
5 Recruiting The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Condition: Homozygous Familial Hypercholesterolemia
Intervention:
6 Unknown † Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
Condition: Heterozigous Familial Hypercholesterolemia
Intervention: Drug: Statins and Ezetimibe
7 Recruiting Cholesterol Lowering Treatment With Psyllium Husks and Isolated Soy Protein in Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: Psyllium husks;   Dietary Supplement: Isolated soy protein;   Dietary Supplement: Isolated whey protein;   Other: Microcrystalline cellulose
8 Not yet recruiting A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: BMS-852927;   Drug: Placebo
9 Recruiting A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: ETC-1002;   Drug: Placebo
10 Not yet recruiting A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia
Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
11 Recruiting A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Conditions: Hypercholesterolemia;   Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg;   Drug: Placebo;   Drug: mipomersen sodium 70 mg
12 Recruiting A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
Condition: Hypercholesterolemia
Interventions: Drug: Ezetimibe;   Drug: Placebo
13 Recruiting Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)
Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727);   Drug: matching placebo SAR236553 (REGN727);   Drug: Ezetimibe;   Drug: matching placebo for Ezetimibe
14 Recruiting Efficacy and Safety Evaluation of SAR236553 (REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin
15 Recruiting Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)
Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727);   Other: Placebo
16 Recruiting Long-term Safety and Tolerability of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: SAR236553 (REGN727)
17 Recruiting Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727);   Other: placebo
18 Recruiting Study of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (Odyssey Alternative)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553);   Drug: Active Comparator 1 (ezetimibe);   Drug: Active Comparator 2 (atorvastatin);   Other: Placebo 1 (placebo for ezetimibe atorvastatin);   Other: Placebo 2 [alirocumab (REGN727/ SAR236553)]
19 Recruiting Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Biological: AMG 145;   Other: Placebo
20 Not yet recruiting Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM1)
Conditions: Hyperlipoproteinemia Type II;   Homozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years